Urine IL-8, Ficolin-3, Apolipoprotein L1, Properdin, and Proteinase 3 also need to be validated both independently and as a multi-marker panel in future cross-sectional and longitudinal cohorts to confirm if they are good indicators for bladder cancer disease progression. This evidence concerns the gene CFP and urinary bladder carcinoma.